Get the Stockscreener App
0.982
0.20%
0.002
Pre-market:
.98
-0.002
-0.20%
Werewolf Therapeutics Inc stock is traded at $0.982, with a volume of 374.79K.
It is up +0.20% in the last 24 hours and up +12.42% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$0.98
Open:
$0.99
24h Volume:
374.79K
Relative Volume:
0.06
Market Cap:
$47.72M
Revenue:
$1.14M
Net Income/Loss:
$-56.27M
P/E Ratio:
-0.809
EPS:
-1.2139
Net Cash Flow:
$-51.94M
1W Performance:
+0.20%
1M Performance:
+12.42%
6M Performance:
+24.94%
1Y Performance:
-46.63%
1-Day Range:
$0.9706
$0.995
1-Week Range:
$0.919
$1.01
52-Week Range:
$0.27
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.982 | 47.72M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Ambros deal would give Werewolf (NASDAQ: HOWL) investors rights to future sales of legacy drug assets - Stock Titan
Werewolf Therapeutics | SCHEDULE 13G: Others - Moomoo
German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
Werewolf Therapeutics stock steadies as investors weigh recent losses and biotech outlook - AD HOC NEWS
Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers - TipRanks
Werewolf Therapeutics (HOWL) Dips 1.43% to $0.97 as Tight Trading Range Sends Stock Toward Key SupportEarnings Miss Risk - dars.gov.et
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
HOWL|Werewolf Therapeutics Inc|Price:0.980|Chg%:+0.014 - TradingKey
Werewolf Therapeutics Stock Price Forecast. Should You Buy HOWL? - StockInvest.us
Werewolf Therapeutics stock gains on merger scrutiny and trial progress - ad-hoc-news.de
HOWL Q2 2026 Earnings: 130% EPS Surprise vs. a 5.46% SelloffPreliminary Results - dars.gov.et
HOWL Q2 2026 Earnings: EPS Beats Estimates by 130%, Shares Edge Down 2.87%Earnings Volatility Report - dars.gov.et
3 Firms Build Biotech Merger With $150M In Private Funding - Law360
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Werewolf (HOWL) Outlook: Moves 102.57% Up to $0.87 in the Latest Reading; Boundary Watch: $0.83 and $0.91 Define the Nearby Reference Levels at the CloseMoving Average Ribbon - vinanet.vn
Werewolf and Ambros Therapeutics announce merger - The Pharma Letter
Werewolf Therapeutics (NASDAQ:HOWL) Deal Changes Pipeline Focus - Kalkine Media
Werewolf Therapeutics Shares Surge Twofold After Ambros Merger, Investors Retain 6.8% Stake - TechStock²
Latham Watkins Advises on Oversubscribed Private Placement in Werewolf Ambros Merger Transaction - Latham & Watkins LLP
Werewolf Therapeutics, Inc. announced that it expects to receive $150 million in funding - marketscreener.com
Werewolf Therapeutics Strikes Reverse Merger With Ambros, Secures $150 Million for Rare Pain Drug - finance.biggo.com
Trending Stocks Today | Werewolf Therapeutics Shoots up 117.27% - Moomoo
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Watertown biotech agrees to reverse merger with Vivek Ramaswamy-backed startup - The Business Journals
Gold Moves Higher; US Composite PMI Surges In August - Benzinga
Werewolf Therapeutics (HOWL) Stock Soars 127% on Ambros Merger and $150M Financing Deal - Blockonomi
Werewolf Therapeutics stock soars on Ambros merger deal and $150 million PIPE - Quiver Quantitative
Why is Werewolf Therapeutics stock surging more than 100% today? By Investing.com - Investing.com Canada
Ambros Therapeutics to merge with Werewolf Therapeutics in all-stock deal - Dealroom
Why is Werewolf Therapeutics stock surging more than 100% today? - Investing.com
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug - Fierce Biotech
Why Is Werewolf Therapeutics Stock Gaining Friday?Werewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Israel Englander's HOWL Stock Soars on $500M DealWerewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Werewolf Therapeutics to Merge and Rebrand as Ambros - TipRanks
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing - Yahoo Finance
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future - StocksToTrade
Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today? - TipRanks
Werewolf (NASDAQ: HOWL) Ambros deal leaves holders with single-digit stake - Stock Titan
Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE, Holders Locked Up - TradingView
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement - Investing News Network
Werewolf Therapeutics stock soars 120% on Ambros merger deal - Investing.com
HOWL Stock Jumps As One-Off Deal Reshapes Outlook - StocksToTrade
HOWL Stock Jumps As One-Time Deal Fuels Q2 Profit - timothysykes.com
Werewolf Therapeutics to merge with Ambros in $150m deal - Investing.com
Werewolf Therapeutics, Ambros Therapeutics Plan Merger With $150 Million Financing - citybiz
Werewolf Therapeutics to merge with Ambros in $150m deal By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Werewolf Therapeutics and Ambros Therapeutics Announce - GlobeNewswire
Top Premarket Gainers - marketscreener.com
Great couple of days trading this!! 🐺 📊 📚 - Moomoo
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Werewolf Therapeutics Inc Stock (HOWL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
Jul 06 '26 |
Sale |
0.32 |
35,770 |
11,446 |
107,429 |
0.14%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):